TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24164779
Drug: Sucrose drinks
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose drinks (4 × 250 ml, total 1800 kJ/d)
Study: 24164779
Drug: Aspartame drinks
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame drinks (4 × 250 ml)
Study: 16189197
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH (0.3 mg . kg(‐1) . d(‐1))
Study: 16189197
Drug: High-dose DEXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DEXA
Study: 16189197
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose DEXA
Study: 1714507
Drug: 6-methylmercaptopurine riboside
Normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylmercaptopurine riboside (MMPR) at 75 mg/m2
Study: 1714507
Drug: 6-methylmercaptopurine riboside
Normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylmercaptopurine riboside (MMPR) at 150 mg/m2
Study: 1714507
Drug: 6-methylmercaptopurine riboside
Normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylmercaptopurine riboside (MMPR) at 225 mg/m2
Study: 30446250
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (n=151) for 12 weeks
Study: 30446250
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n=156) for 12 weeks
Study: 24768191
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 1 g/d
Study: 24768191
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin with laropiprant (ERN/LRP) 1 g/20 mg
Study: 16187006
Drug: Propionyl-L-carnitine (PC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PC) 24 mg/kg b.w.
Study: 16187006
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) 20 mg/kg b.w.
Study: 9161626
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times daily for seven days
Study: 9161626
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times daily for seven days among patients 50 years or older
Study: 30171698
Drug: 0.03% resiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% resiquimod gel once-daily application three times per week for 4 weeks
Study: 30171698
Drug: 0.03% resiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% resiquimod gel seven times within 2 weeks
Study: 30171698
Drug: 0.03% resiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% resiquimod gel five times for 1 week
Study: 30171698
Drug: 0.01% resiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Study: 30171698
Drug: 0.03% resiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Study: 25833957
Drug: Daunorubicin 90
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 90 mg/m2
Study: 25833957
Drug: Daunorubicin 60
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 60 mg/m2
Study: 19167733
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg per day) during oral phase A
Study: 19167733
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during oral phase A
Study: 19167733
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg per day) during oral phase B
Study: 19167733
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during oral phase B
Study: 14641105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/day for 8 weeks
Study: 11248742
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment at a mean dose of 0.32 mg/kg per week for 1 year
Study: 11248742
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum total IGF‐I levels
Study: 8201372
Drug: Hydrazine sulfate
Normalized name: Hydrazine Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrazine sulfate 60 mg three times per day orally
Study: 26098419
Drug: Rhodiola crenulata
Normalized name: RHODIOLA CRENULATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola crenulata (RC) 250 mg twice/day (n=38)
Study: 26098419
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg twice/day) (n=19)
Study: 19894330
Drug: Calcium 1500
Normalized name: calcium citrate 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1500 g/day + alfacalcidol 0.5 mg/day
Study: 19894330
Drug: Calcium 1500
Normalized name: calcium citrate 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1500 g/day + placebo
Study: 16720058
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m2 on days 1 and 8) and cisplatin (80 mg/m2 on day 8) every 3 weeks
Study: 15100375
Drug: Normal hemoglobin
Normalized name: Abnormal hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hemoglobin group (target hemoglobin of 14 +/- 1 g/dl)
Study: 15100375
Drug: Anemic hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemic hemoglobin group (target hemoglobin of 10 +/- 1 g/dl)
Study: 8547417
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (1 megaunit weekly for 4 weeks)
Study: 2501813
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (Nicorette; average of 6.9 pieces per day)
Study: 30496578
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D3 (adjusted to maintain serum 25(OH)D >75 nmol/L)
Study: 26034983
Drug: ESM self‐monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESM self‐monitoring combined with weekly PA‐focused feedback sessions
Study: 26034983
Drug: ESM self‐monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESM self‐monitoring combined with six weekly sessions without feedback
Study: 24955642
Drug: Astaxanthin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (2 mg/day) combined with collagen hydrolysate (3 g/day)
Study: 22499290
Drug: Chlortalidone (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortalidone (12.5-25 mg daily)
Study: 22499290
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive medications (excluding thiazides)
Study: 17620073
Drug: 3-year subcutaneous
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-year subcutaneous specific immunotherapy (SIT) with standardized allergen extracts of grass and/or birch
Study: 17620073
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific immunotherapy (Control)
Study: 9836561
Drug: Testicular androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testicular androgen ablation (bilateral orchiectomy in 15 and luteinizing hormone‐releasing hormone analogue in 3)
Study: 9836561
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/day) alone or in combination with flutamide (250 mg three times a day)
Study: 1918555
Drug: General coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: General coping preparation package (PREP)
Study: 1918555
Drug: Routine clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinic treatment only
Study: 6173904
Drug: Chemotherapy (MOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (MOPP + LDB)
Study: 6173904
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (MOPP + LDB + XRT)
Study: 30902420
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg (400 IU) vitamin D supplementation
Study: 30902420
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg (1200 IU) vitamin D supplementation
Study: 30902420
Drug: High cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cord blood 25-hydroxyvitamin D (≥100 nmol/L)
Study: 24413638
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β‐1a, 44 μg sc three times weekly or once weekly, for 24 months or until diagnosis of clinically definite multiple sclerosis (CDMS)
Study: 17588396
Drug: Methylprednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (15 mg/kg)
Study: 11454380
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg gemfibrozil daily for 6 weeks
Study: 11454380
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fenofibrate daily for 6 weeks
Study: 2808867
Drug: Plain lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lidocaine solution
Study: 1208040
Drug: Glutathione‐bicarbonate‐Ringer's (GBR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione‐bicarbonate‐Ringer's (GBR) solution
Study: 26130623
Drug: Oral ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ambroxol (40 mg/kg/day, in four divided doses)
Study: 21712501
Drug: No/low intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No/low intervention dose
Study: 21712501
Drug: Medium intervention
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium intervention dose
Study: 21712501
Drug: High intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intervention dose
Study: 18618371
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg ramosetron hydrochloride once daily for 12 weeks
Study: 8103648
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with thiopental (2‐4 mg/kg) and low fentanyl dose (5 micrograms/kg)
Study: 8103648
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with thiopental (2‐4 mg/kg) and high fentanyl dose (30 micrograms/kg)
Study: 3785608
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available medical therapy
Study: 22494879
Drug: Nicotine and
Normalized name: lovastatin and nicotinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine and alcohol co-administration
Study: 16234451
Drug: Pressure topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure topical anaesthesia
Study: 16234451
Drug: Injection anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anaesthesia
Study: 12167550
Drug: Risperidone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.75 mg)
Study: 10459902
Drug: Cationic lipid-mediated
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cationic lipid-mediated CFTR gene transfer (active treatment)
Study: 31759193
Drug: PQ912 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PQ912 treatment (glutaminylcyclase inhibitor)
Study: 19784511
Drug: 4 L.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L.min‐1 of oxygen (Group O)
Study: 10642349
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 to 16 mg daily)
Study: 3520129
Drug: Maltitol (10g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol (10g 3 times daily for 5 days)
Study: 31545373
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies in single-arm trials
Study: 31545373
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with observed rates 10 percentage points higher than upper targets
Study: 31545373
Drug: Single-arm combination
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-arm combination trials
Study: 22257614
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR treatment strategy
Study: 22257614
Drug: Atenolol treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol treatment strategy
Study: 22257614
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment strategies
Study: 20169490
Drug: Water suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water suppression system (0.13, 0.06, 0.03, or 0.02 L/sec of water)
Study: 20169490
Drug: No control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No control treatment
Study: 18023335
Drug: Formoterol (2x9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (2x9 microg lower dose; 6x9 microg higher dose)
Study: 18023335
Drug: Salbutamol (3x400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (3x400 microg lower dose; 9x400 microg higher dose)
Study: 12757028
Drug: Ozonated autohemotherapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated autohemotherapy with ozone concentration 50 microg/ml per gram of blood
Study: 11134094
Drug: 0.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/day micronized 17ss-estradiol
Study: 11134094
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day micronized 17ss-estradiol
Study: 11134094
Drug: 1.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/day micronized 17ss-estradiol
Study: 9079233
Drug: Lisinopril treatment
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril treatment
Study: 9079233
Drug: Lisinopril/hydrochlorothiazide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide treatment
Study: 9079233
Drug: Intensified non-pharmacological
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified non-pharmacological treatment
Study: 9079233
Drug: Previous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous or adjusted medication
Study: 3717956
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (CDDP 75 mg/m2 and ADM 50 mg/m2 every 4 weeks)
Study: 3717956
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (CDDP 75 mg/m2, ADM 50 mg/m2, plus VCR 1.4 mg/m2 on day 1 and 0.7 mg/m2 on day 7 every 4 weeks)
Study: 30516797
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy plus sertraline
Study: 27779776
Drug: Sildenafil 10
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 10 mg as a bolus followed by 2.5 mg infusion over 2 hours
Study: 27779776
Drug: Sildenafil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil doses (2.5 mg, 5 mg, 10 mg)
Study: 23601186
Drug: Oral paricalcitol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paricalcitol, 2 μg per day for the first year posttransplant
Study: 23601186
Drug: Oral paricalcitol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paricalcitol, 2 μg per day
Study: 16689086
Drug: Central neurotropic
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central neurotropic preparations in addition to routine medicines
Study: 16689086
Drug: Routine preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine preparations only
Study: 29979803
Drug: Oxycodone and
Normalized name: oxycodone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone and acetaminophen PRN
Study: 29979803
Drug: Oxycodone and
Normalized name: oxycodone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone and acetaminophen with specific dosing
Study: 29979803
Drug: Oxycodone, acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone, acetaminophen, and OxyContin with specific dosing
Study: 29979803
Drug: Oxycodone, acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone, acetaminophen, and ketorolac with specific dosing
Study: 26190830
Drug: Subcutaneous agar‐filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous agar‐filled needle with calomel (Ndl)
Study: 26190830
Drug: Dermal abrasion
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal abrasion with conducting cream and Ag/AgCl electrodes (Abr)
Study: 24636266
Drug: Standard guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guidelines for antibiotic therapy (Control)
Study: 22120765
Drug: Nebulized L-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized L-epinephrine 0.5 ml
Study: 22120765
Drug: Nebulized L-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized L-epinephrine 2.5 ml
Study: 22120765
Drug: Nebulized L-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized L-epinephrine 5 ml
Study: 12187023
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma-1b (IFN-gamma), given subcutaneously at a dose of 50 microg/m(2) daily for 30 days.
Study: 1767176
Drug: Troxerutin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin (4 g/d)
Study: 30068263
Drug: Pomalidomide and
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide and low-dose dexamethasone
Study: 23429358
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose)
Study: 22819265
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (300 mg loading dose)
Study: 19914566
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5-FU) based adjuvant chemotherapy
Study: 16296924
Drug: Kampo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo therapy for 12 weeks
Study: 8824645
Drug: Lactose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (1 L of milk)
Study: 8824645
Drug: Pre-hydrolyzed milk
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hydrolyzed milk and lactase preparations
Study: 1775676
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release salbutamol (SCR) 8 mg twice daily for 6 weeks
Study: 7318626
Drug: Cefamandole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole treatment in 112 patients
Study: 31395808
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (kinesitherapy with therapy dog)
Study: 31395808
Drug: Kinesitherapy (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesitherapy (without therapy dog)
Study: 17582255
Drug: Esomeprazole-based 1
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole-based 1 week triple therapy
Study: 17582255
Drug: Esomeprazole-based 2
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole-based 2 weeks triple therapy
Study: 1907549
Drug: Piroxicam, 20
Normalized name: Piroxicam, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam, 20 mg day‐1
Study: 28629397
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of renal replacement therapy (RRT)
Study: 28629397
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of renal replacement therapy (RRT)
Study: 26926372
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO) combined with high-dose dexamethasone (40 mg intravenously d1-4) and rhTPO (300 U·kg(‐1)·d(‐1) subcutaneously d1-14)
Study: 26926372
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (40 mg intravenously d1-4)
Study: 24570273
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice concentrate (30 ml diluted to 250 ml with water)
Study: 17301566
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA < 50 IU/ml at week 4
Study: 17301566
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA < 600 IU/ml at week 4
Study: 17301566
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA > 50 IU/ml at week 4